Real-World Immuno-Radiotherapy for Advanced NSCLC

CompletedOBSERVATIONAL
Enrollment

338

Participants

Timeline

Start Date

January 1, 2015

Primary Completion Date

December 1, 2024

Study Completion Date

December 1, 2024

Conditions
Lung Cancer Non-Small Cell Cancer (NSCLC)
Interventions
DRUG

initial Sequential iRT

"For unresectable locally advanced NSCLC, definitive thoracic radiotherapy must have been administered as the initial treatment, with immunotherapy initiated within 90 days after RT.~For de novo metastatic NSCLC, radiotherapy targeting the primary lung tumor or metastatic lesions must have been administered as the initial treatment, with immunotherapy initiated within 90 days."

DRUG

initial Concurrent iRT

"For unresectable locally advanced NSCLC, definitive thoracic radiotherapy must have been administered as the initial treatment, with immunotherapy concurrently with RT.~For de novo metastatic NSCLC, radiotherapy targeting the primary lung tumor or metastatic lesions must have been administered as the initial treatment, with immunotherapy concurrently with RT."

DRUG

RT with maintenance of ICI

For post-treatment progressive NSCLC, salvage radiotherapy performed during immunotherapy.

DRUG

RT after discontinuation of ICI

For post-treatment progressive NSCLC, salvage radiotherapy performed during within 90 days after the cessation of immunotherapy.

Trial Locations (1)

999077

Queen Mary Hospital, Hong Kong

All Listed Sponsors
lead

Fengming Kong

OTHER

NCT06747026 - Real-World Immuno-Radiotherapy for Advanced NSCLC | Biotech Hunter | Biotech Hunter